Delving into the Latest Updates on Hydrocortisone with Synapse

Overview

Basic Info

SummaryHydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR. This drug boasts a diverse range of clinical applications and is typically employed in the treatment of a multitude of ailments that are closely associated with adrenal insufficiency, including but not limited to congenital adrenal hyperplasia, adrenal hyperplasia, Addison's disease, and isolated ACTH deficiency. Additionally, it has proven efficacious in treating inflammatory conditions such as subacute thyroiditis, ulcerative colitis, proctocolitis, and ulcerative proctitis. It is worth noting that the FDA initially granted its approval to hydrocortisone on the 5th of August, 1952. The development of hydrocortisone is credited to Merck Sharp & Dohme Corp, which pioneered the drug. Owing to its extraordinary anti-inflammatory and immunosuppressive qualities, hydrocortisone has emerged as a definitive remedy for numerous chronic inflammatory disorders.

Drug Type

Small molecule drug

Synonyms

(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione, 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione, 11beta-hydrocortisone

+ [60]

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [5]

Active Indication

EczemaAdrenal Hyperplasia, CongenitalInsect Bites and Stings+ [8]

Inactive Indication

Addison DiseaseAdult Lymphoblastic LymphomaAnaphylaxis+ [16]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Vivozon Pharmaceutical Inc.

ANI Pharmaceuticals, Inc.

Pfizer Japan, Inc.

+ [4]

Inactive Organization

Pharmacia & Upjohn, Inc.

Takeda Pharmaceutical Co., Ltd.

Merck & Co., Inc.

+ [3]

License Organization

TOLMAR Holding, Inc.

Immedica Group Ltd.

ExCEEd Orphan sro

+ [11]

Drug Highest PhaseApproved

First Approval Date

United States (05 Aug 1952),

Endocrine System DiseasesHypersensitivityImmune System Diseases+ [1]

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia)

Login to view timeline

Structure/Sequence

Molecular FormulaC21H30O5

InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N

CAS Registry50-23-7

This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.

Start Date01 Oct 2026

Sponsor / Collaborator

Wayne State University (Michigan)

NCT07498465

/ WithdrawnPhase 1IIT

A Phase 1 Trial of the Menin Inhibitor SNDX-5613 (Revumenib) (NSC# 852942) for Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

This phase I trial tests the safety, best dose, and effectiveness of revumenib given as maintenance therapy after standard hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia, acute myeloid leukemia, or mixed phenotype acute leukemia. Revumenib binds to a protein called menin, which prevents menin from interacting with another protein called MLL. This results in an inhibition of the proliferation of leukemic cells with certain genetic alterations. Revumenib may inhibit the survival, growth, transformation and proliferation of certain kinds of leukemia cells. It is approved for the treatment of patients with certain types of acute leukemia, but it is not approved for maintenance therapy (treatment that aims to prevent cancer from coming back) after HSCT.

Start Date10 Sep 2026

Sponsor / Collaborator

The Children's Oncology Group Foundation, Inc.

NCT07072585

/ Not yet recruitingPhase 2/3IIT

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.

Start Date28 Aug 2026

Sponsor / Collaborator

The Children's Oncology Group Foundation, Inc.

100 Clinical Results associated with Hydrocortisone

Login to view more data

100 Translational Medicine associated with Hydrocortisone

Login to view more data

100 Patents (Medical) associated with Hydrocortisone

Login to view more data

59,870

Literatures (Medical) associated with Hydrocortisone

01 Feb 2027·TALANTA

Touch-based wearable cortisol monitoring via an interface-engineered hydrogel fiber sensor

Article

Author: Hou, Chengyi ; Li, Kerui ; Li, Yaogang ; Tian, Hang ; Chen, Shihui ; Wang, Hongzhi ; Shao, Zhuwang ; Zhang, Qinghong ; Qu, Lingli

Wearable cortisol monitoring offers a noninvasive approach for assessing dynamic physiological stress, but reliable on-body analysis remains challenging owing to limited sweat availability, unstable electrode contact, and use-induced mechanical deformation. Here, we report a compartmentalized multi-lumen, hydrogel-integrated cortisol-sensing fiber (HCSF) for rapid and reliable detection of cortisol in sweat that combines sweat collection, molecular recognition, and wireless readout in a glove-based wearable platform. The interface-engineered interlayer provides topological anchoring for the MIP matrix and promotes efficient charge transfer, while the porous compartmentalized hydrogel sheath functions as an in situ sweat collector, hydrated ion-conducting medium, electrode spacer, and mechanical buffer, collectively stabilizing the fiber-polymer interface under repeated bending. With Prussian blue embedded in the MIP network as an internal redox probe, the sensor enables label-free quantitative cortisol detection through steric-hindrance-mediated signal modulation, achieving a low limit of detection of 0.87 pM and a broad linear range from 1 pM to 10 μM. After integration into a wearable glove with a miniaturized wireless readout module, the platform tracks dynamic cortisol fluctuations during physical exercise and acute cold-pressor tests. This robust and ergonomically integrated platform provides a promising strategy for noninvasive endocrine monitoring and personalized stress assessment.

31 Dec 2026·Adipocyte

Wt1 facilitates visceral beige fat formation to combat abdominal obesity

Article

Author: He, Lin-Fei ; Chen, Jun-Ling ; Yang, Zhi-Chun ; Liao, Zhi-Mei

Visceral fat has weaker beige adipogenesis than subcutaneous fat with unclear mechanisms. The Wilms tumour gene (Wt1), a visceral adipocyte marker, is highly expressed in visceral adipose tissue (VAT) and visceral adipose-derived stem cells (vADSCs). In our present study, we found its protein levels in VAT decreased under high-fat diet or dexamethasone treatment, but rised in cold exposure or β3-adrenergic receptor agonist treatment, and positively correlate with uncoupling protein-1 (UCP1). Wt1 knockdown in vADSCs elevated PR domain containing 16 (PRDM16) and UCP1 mRNA but reduced their protein levels, alongside decreased ubiquitin-conjugating enzyme 9 (UBC9). Knockdown of UBC9 did not affect the mRNA levels of Wt1, PRDM16 or UCP1, but significantly reduced PRDM16 and UCP1 protein levels. Glucocorticoids including hydrocortisone, methylprednisolone and dexamethasone (Dex) dose-dependently suppress Wt1, UCP1, Alpha-enolase (ENO1) and Pyruvate kinase muscle isozyme M2 (PKM2) levels, which could be reversed by Wt1 overexpression. These findings explore the effects of Wt1 on beige remodelling of visceral adipose which might be related to the up-regulation of UBC9, and provide clues for treating abdominal obesity caused either by HFD or by glucocorticoids in a non-sympathetic-dependent manner.

01 Dec 2026·Medical Gas Research

Effects of non-intubated spontaneous breathing on cerebral oxygen saturation and postoperative cognition in elderly patients with lung cancer undergoing video-assisted thoracoscopic surgery

Article

Author: Zhang, Yufan ; Zhang, Lei ; Lao, Yuwen

JOURNAL/mgres/04.03/01612956-202612000-00009/figure1/v/2026-08-11T211952Z/r/image-tiff Video-assisted thoracoscopic surgery during one-lung ventilation may impair cerebral oxygen balance and increase the risk of postoperative cognitive impairment. This perspective study aimed to analyze the effect of non-intubated anesthesia with preserved spontaneous breathing on cerebral oxygen saturation and postoperative cognitive dysfunction in elderly patients with lung cancer during video-assisted thoracoscopic surgery. A total of 104 elderly patients with lung cancer who underwent video-assisted thoracoscopic surgery in Jinhua Municipal Central Hospital from January 2023 to October 2024 were selected, and they were randomly divided into non-intubated group ( n = 52) and intubated group ( n = 52). The cerebral oxygen saturation, postoperative cognitive dysfunction incidence and laboratory indicators were compared between the two groups. At last, the influencing factors to postoperative cognitive dysfunction were analyzed by multivariate Logistic regression. The cerebral oxygen saturation was higher at 15, 30 and 60 minutes after operation than at the beginning of anesthesia, and moreover, it in the non-intubation group were significantly higher than that in the intubated group ( P < 0.05). At 72 hours after operation, the levels of tumor necrosis factor-α, interleukin-6 and S100β in serum were lower than those before operation, and the levels in the non-intubated group were significantly lower than those in the intubated group; the levels of epinephrine, atrial natriuretic peptide and cortisol in serum were higher than those before operation, and they in the non-intubated group were significantly more than those in the intubated group ( P < 0.05). The total incidence of postoperative cognitive dysfunction in intubation group was higher than that in the non-intubated group within 2 months after operation ( P < 0.05). Multivariate Logistic regression analysis showed that age (odds ratio = 1.729), cerebral oxygen saturation at 30 minutes after operation (odds ratio = 0.727) and cerebral oxygen saturation at 60 minutes after operation (odds ratio = 0.734) were independent influencing factors for postoperative cognitive dysfunction (all P < 0.05). Non-tracheal intubation anesthesia with preserved spontaneous breathing can increase cerebral oxygen saturation, reduce systemic inflammatory response and stress response, and decrease the incidence of postoperative cognitive dysfunction in elderly patients with lung cancer undergoing video-assisted thoracoscopic surgery, which is conducive to promoting postoperative recovery in such patients.

184

News (Medical) associated with Hydrocortisone

14 Sep 2026

·www.sciencedaily.com

Scientists find a hidden cause of high blood pressure that routine tests can miss

A wearable device has revealed nighttime hormone surges that may expose a frequently missed cause of high blood pressure. The discovery could help explain why primary aldosteronism often escapes standard blood tests and point toward a more accurate way to diagnose it.A common and frequently missed cause of high blood pressure may be easier to detect with help from a wearable device that tracks hormone changes throughout the day and night. New research published in Science Translational Medicine focuses on primary aldosteronism, a hormone disorder that may affect up to one in five people with high blood pressure. The condition is associated with an increased risk of heart disease, stroke, diabetes, and other serious health problems. Researchers from the University of Bristol and the University of Manchester in the UK, the University of Bergen in Norway, and collaborators in Stockholm and Athens found that people with primary aldosteronism can experience bursts of hormone production both during the day and while asleep at night. Those nighttime surges are especially important because routine blood tests are rarely performed during sleep. A Wearable Device Tracks Hormones Around the Clock To capture these hidden changes, the research team used a portable device developed at the University of Bristol that allowed patients to have their hormone levels monitored continuously while living normally at home rather than staying in a hospital or research facility. This type of continuous monitoring could reveal abnormalities that may be missed by conventional testing, potentially helping doctors identify hormone-related conditions earlier. Study co-lead author Dr. Thomas Upton, Clinical Research Fellow in Automated Sampling Clinical Fellow at the University of Bristol, and Senior Clinical Fellow at Bristol Hospitals NHS Foundation Trust said: "Primary aldosteronism is an important cause of high blood pressure and the most common cause of secondary hypertension we see in our blood pressure clinic. It could be affecting millions of people in the UK. However, due to the way hormones change during the day and the current complexity of the diagnostic process, diagnosis is often delayed or never made at all. "In our study, patients were monitored at home during normal activity, and this allowed us to see how hormones changed over time in realistic settings. This approach could potentially revolutionize how we diagnose hypertension and ultimately reduce cardiovascular disease - particularly heart disease and strokes - that could have been prevented." Measuring Hormones Every 20 Minutes The proof-of-concept study followed 60 patients in Bristol, Bergen, Stockholm, and Athens over a 24-hour period. Hormone levels were measured every 20 minutes using a lightweight wearable device about the size of a mobile phone that attaches at the waist. Because the device samples hormones from the skin, participants were able to continue with their usual activities, including sleeping at night, while researchers collected detailed hormone data. The technology, known as U-RHYTHM, was adopted and further developed by the spinout company Dynamic Therapeutics in 2023. Study senior author Dr. Eder Zavala, UKRI Future Leader Fellow at the University of Manchester, said: "By continuously monitoring hormones over 24 hours, we were able to reveal a previously hidden pattern of nocturnal hormone bursts. This gives us a much clearer understanding of the disease and could ultimately help doctors detect it earlier and treat patients more effectively. "A more detailed mathematical and computational analysis of daily hormonal profiles could eventually also help uncover earlier and more subtle forms of the disease, opening new opportunities to improve outcomes for patients living with high blood pressure." Why Standard Blood Tests May Miss the Disorder Researchers used computational analysis to study changes in aldosterone, a hormone that helps control salt and water balance in the body. They also tracked two closely related hormones, 18-hydroxycortisol and 18-oxocortisol. The results suggest that current diagnostic approaches may miss some patients because aldosterone does not remain consistently elevated. Even in some of the most severe cases, hormone levels sometimes dropped below the minimum thresholds typically used to diagnose primary aldosteronism. A single blood test taken at one moment could therefore capture a period when hormone levels appear relatively normal. Instead of remaining constantly high, aldosterone showed repeated bursts of secretion at night while the overall day-night rhythm of hormone activity remained intact. Nighttime Hormone Bursts Offer a New Clue The hormone spikes came from the adrenal glands and were especially pronounced in patients whose primary aldosteronism was caused by a problem affecting only one adrenal gland rather than both. Importantly, the unusual hormone patterns disappeared after the affected adrenal gland was surgically removed. That finding provided additional evidence that the bursts were directly associated with the disease. Study co-author Prof Stafford Lightman, Professor of Medicine at the University of Bristol and inventor of the U-RHYTHM technology, added: "The findings suggest that clinicians may need to rethink how they look for the disorder, which the Endocrine Society clinical practice guidelines now recommend should be considered for all people with hypertension, also known as high blood pressure. "Future diagnosis could move away from single time point blood tests and towards tracking the body's hormone rhythms over time, particularly the overnight patterns that appear to hold crucial clues to disease. Further research is needed to define the best clinical pathways, using dynamic hormone measurement, to ensure early diagnosis of this common and potentially curable cause of high blood pressure." Toward Earlier Detection of High Blood Pressure Causes The findings raise the possibility that future testing for primary aldosteronism could rely less on a single blood sample and more on monitoring how hormones change over time. Because the disorder can be treated and, in some cases, potentially cured, detecting it earlier could help reduce the risk of preventable cardiovascular complications. The research was funded by EU Horizon 2020, the Trond Mohn Foundation, the UKRI Biotechnology and Biological Sciences Research Council (BBSRC), Medical Research Council, University Hospitals Bristol and Weston NHS Foundation, the Swedish Medical Research Council and Knut and Alice Wallenberg Foundation. The findings support the University of Bristol's research 'Grand Challenge' focus on Understanding and Preventing Cardiovascular Disease and builds on NIHR-funded initiatives aimed at earlier identification of people with hypertension and other cardiovascular risk factors.

05 Sep 2026

·www.prnewswire.com

Best Hair Growth Products for Men (2026): Happy Head Personalized Formulas Reviewed by Consumer365

NEW YORK, Sept. 5, 2026 /PRNewswire/ -- Consumer365 has reviewed Happy Head for its personalized approach to prescription hair-growth treatment, highlighting a selection of dermatologist-guided formulas designed for men managing thinning hair and male pattern hair loss. Best Hair Growth Products for Men Happy Head - a telehealth provider of personalized, dermatologist-prescribed hair-loss treatments Hair loss treatment has become increasingly personalized as prescription medicine moves into telehealth. Instead of relying on a single standardized formula, Happy Head connects customers with board-certified dermatologists who review medical history, allergies, hair-loss patterns and treatment goals before prescribing a personalized regimen. Treatments are then compounded and shipped directly to the customer. The approach is particularly relevant for consumers researching the best hair growth products for men, a category that includes topical treatments, oral medications and combination regimens. Happy Head offers each format through a telehealth model that does not require an in-person doctor visit. Happy Head offers personalized compounded formulas including dutasteride, finasteride, minoxidil to help you achieve your personal hair growth goals. Consumer365 Recognizes Happy Head's Personalized Treatment Model Consumer365 has recognized Happy Head for combining prescription hair-growth medicine with dermatologist oversight and personalized formulations. Happy Head states that all consultations are conducted by board-certified doctors. The platform also provides ongoing dermatologist support, allowing treatment formulas to be adjusted when medically appropriate. The company's formulations use FDA-approved active pharmaceutical ingredients, although compounded prescription formulations themselves are not FDA-approved. Happy Head's website identifies ingredients such as finasteride and minoxidil among its prescription options. The distinction is important for consumers evaluating prescription hair-loss care. The active ingredients may have established clinical uses, while compounded combinations require individualized medical oversight and are not equivalent to an FDA-approved finished drug product. Happy Head says most customers begin seeing progress within three to six months of consistent daily use. Early changes may include reduced shedding or the appearance of fine new hairs. Individual responses and timelines can vary. TopicalRx SuperSolutionTM ProBlend Topical Rx SuperSolution TM ProBlend is designed for consumers seeking a multi-ingredient topical prescription formula. The formulation includes up to 8% minoxidil alongside ingredients such as dutasteride, finasteride, cetirizine HCl, latanoprost, melatonin, caffeine, tretinoin, vitamin D3 and biotin. The formula is intended to address multiple aspects of hair and scalp health through a single topical treatment. Minoxidil is used to support hair growth, while dutasteride and finasteride target DHT, a hormone associated with male pattern hair loss. Tretinoin is included in the formulation to support minoxidil absorption. Happy Head describes its topical formulations as freshly compounded prescriptions rather than mass-produced products. Formula adjustments are available based on a customer's medical needs and dermatologist assessment. A higher concentration of an active ingredient does not automatically make a treatment appropriate for every person. Prescription-strength formulations require evaluation by a qualified healthcare provider. TopicalRx Solution + SuperCapsuleTM: Dutasteride & MinoxidilRx For men interested in combining topical and oral treatment, Happy Head offers Topical Rx Solution + SuperCapsule TM. The topical solution can contain 0.3% dutasteride, up to 8% minoxidil, retinoic acid and hydrocortisone. The accompanying SuperCapsule contains 0.5 mg dutasteride, 1.25 mg minoxidil and 2,000 IU of vitamin D3. The two-part regimen uses different delivery methods. The topical formula is applied directly to the scalp, for a total of 2.0ml daily, while the capsule provides oral medication once daily. Dutasteride and minoxidil are prescription medications that can carry risks and potential side effects, making medical screening an important part of the process. Happy Head's telehealth assessment is designed to determine whether a prescription treatment is appropriate. Medical history, allergies and the degree of hair loss are among the factors considered during the consultation. SuperCapsuleTM + ED Performance SuperCapsule TM + ED Performance takes a different approach by combining hair-loss treatment with medication for erectile dysfunction in a once-daily capsule. The formulation contains dutasteride, tadalafil and vitamin D3. Dutasteride is used in hair-loss treatment, while tadalafil is a prescription medication used for erectile dysfunction. Happy Head developed the combination for men seeking an oral hair-growth option alongside treatment for sexual performance concerns. The combination also underscores the importance of medical screening. Tadalafil can interact with certain medications and may not be appropriate for people with particular cardiovascular conditions. A dermatologist or other qualified healthcare professional can assess whether the treatment is suitable. The product provides an alternative to a topical routine for men who prefer oral medication. As with other prescription hair-growth treatments, outcomes can vary and consistent use is necessary for evaluating progress. What Sets the Happy Head Model Apart Happy Head's approach centers on prescription treatment supported by telehealth rather than a one-size-fits-all regimen. Customers complete an online assessment before connecting with a board-certified dermatologist. Once a prescription is approved, the treatment is prepared and shipped directly to the customer. Happy Head reports that more than 1 million prescriptions have been delivered through its platform. The company also says its treatments are shipped monthly in discreet packaging, with refills automatically sent as part of eligible subscriptions. Pricing varies according to the formulation and ingredients. Happy Head currently lists custom compounded prescription formulas ranging from $59 to $119 per month. Promotional savings and subscription terms can change over time. For consumers comparing the best hair growth products for men, the key consideration is not simply the number of ingredients or strength of a formula. Hair loss can have different causes, and prescription medications have different safety considerations. A dermatologist-guided assessment can help determine whether topical medication, oral treatment or a combination approach is appropriate. Consumer365's recognition of Happy Head highlights the growing role of personalized telehealth in hair-loss care. With multiple prescription formats and dermatologist oversight, the platform gives men a range of treatment pathways while keeping medical evaluation central to the process. The full review is available at the Consumer365 website. Happy Head offers personalized compounded prescription treatments. Compounded medications are not FDA-approved, and some ingredients or uses discussed may be prescribed off-label. Treatment suitability and results vary. A licensed healthcare provider must determine whether a treatment is appropriate. Review Happy Head's Drug Safety & Information. About Happy Head Happy Head is the industry-leading, dermatologist-founded telehealth company redefining the future of precision hair care. Founded in 2021 by renowned dermatologists and hair loss experts, Dr. Ben Behnam and Dr. Sean Behnam, the company combines clinical expertise with breakthrough science to deliver personalized solutions for hair preservation and restoration. From custom-compound topicals to its innovative StrandIQ™ DNA Starter Kit, Happy Head empowers individuals to make informed decisions to take control of their hair health journey from the privacy of their home, with recommendations that are clinically proven and tailored to individual needs. The mission is simple: help people regrow their hair and restore their confidence with personalized, medical-grade treatments that actually work. Learn more at . About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided. SOURCE Consumer365.org 21% more press release views with Request a Demo

Drug Approval

27 Aug 2026

·www.biospace.com

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI ® , INCRELEX ® , ALKINDI SPRINKLE ® , DESMODA™, GALZIN ® , HEMANGEOL ® , PKU GOLIKE ® , IMPAVIDO ® (September 2026 launch), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ASN-001, AMGLIDIA ® , ET-700, ET-800, and ZENEO ® hydrocortisone autoinjector. For more information, please visit our website at . Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals.

100 Deals associated with Hydrocortisone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00088	Hydrocortisone	D07AA02 A01AC03 S02BA01	DB00741

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Eczema	South Korea	Vivozon Pharmaceutical Inc.	08 May 2026
Adrenal Hyperplasia, Congenital	European Union	Immedica Pharma AB	27 May 2021
Adrenal Hyperplasia, Congenital	Iceland	Immedica Pharma AB	27 May 2021
Adrenal Hyperplasia, Congenital	Liechtenstein	Immedica Pharma AB	27 May 2021
Adrenal Hyperplasia, Congenital	Norway	Immedica Pharma AB	27 May 2021
Insect Bites and Stings	South Korea	Vivozon Pharmaceutical Inc.	20 Jul 1981
Pruritus	South Korea	Vivozon Pharmaceutical Inc.	20 Jul 1981
ACTH Deficiency, Isolated	Japan	Pfizer Japan, Inc.	21 Dec 1972
Adrenal Insufficiency	Japan	Pfizer Japan, Inc.	21 Dec 1972
Infectious Diseases	Japan	Pfizer Japan, Inc.	21 Dec 1972
Thyroiditis, Subacute	Japan	Pfizer Japan, Inc.	21 Dec 1972
Colitis, Ulcerative	United States	ANI Pharmaceuticals, Inc.	12 Jan 1966
Proctocolitis	United States	ANI Pharmaceuticals, Inc.	12 Jan 1966
Ulcerative proctitis	United States	ANI Pharmaceuticals, Inc.	12 Jan 1966
Anaphylaxis	United States	Pharmacia & Upjohn, Inc.	15 Dec 1952
Collagen Diseases	United States	Pharmacia & Upjohn, Inc.	15 Dec 1952
Edema	United States	Pharmacia & Upjohn, Inc.	15 Dec 1952
Eye Diseases	United States	Pharmacia & Upjohn, Inc.	15 Dec 1952
Gastrointestinal Diseases	United States	Pharmacia & Upjohn, Inc.	15 Dec 1952
Hematologic Diseases	United States	Pharmacia & Upjohn, Inc.	15 Dec 1952

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchopulmonary Dysplasia	NDA/BLA	European Union	Laboratoire Aguettant SAS	-
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	Phase 3	United States	-	04 Oct 2018
Addison Disease	Phase 2	Germany	-	23 Nov 2021
Addison Disease	Phase 2	United Kingdom	-	23 Nov 2021
Adult Lymphoblastic Lymphoma	Phase 1	United States	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
Recurrent Childhood Acute Lymphoblastic Leukemia	Phase 1	United States	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
refractory acute lymphoid leukemia in relapse	Phase 1	United States	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
Refractory Adult Acute Lymphoblastic Leukemia	Phase 1	United States	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
Depressive Disorder, Major	Clinical	United States	Wyeth AB	01 Aug 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05222152 (CHAMPAIN, Pubmed \| EClinicalMedicine)	Phase 4	Adrenal Insufficiency	58	Chronocort	jbsrhtitrg(cqkgfkxuxs) = eoeewsrbxw udjbyajokq (upjkieqbzx )	Positive	01 Jan 2026
				Plenadren	jbsrhtitrg(cqkgfkxuxs) = mrwhlcojpd udjbyajokq (upjkieqbzx )
NCT03896659 (CTgov)	Phase 4	Depressive Disorder	66	Hydrocortisone (Depressed: Hydrocortisone)	jwqdtwuvth(zcabsunkqh) = jagjrxsyjt jjcftgfxkm (jjojyoqyzf, 0.76) View more	-	16 Dec 2025
				Placebo+Hydrocortisone (Depressed: Placebo)	jwqdtwuvth(zcabsunkqh) = ompwwdtlab jjcftgfxkm (jjojyoqyzf, 0.25) View more
NCT05063994 (CONnECT, CTgov)	Phase 3	Adrenal Hyperplasia, Congenital \| Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	55	Placebo+Chronocort (Chronocort)	wxicjotubc = hxxoyscyjx fveedmoknd (lqgewsnouc, uivhajjxpy - bcbevbskxw) View more	-	24 Feb 2025
				Placebo+Cortef (Cortef)	wxicjotubc = wgiyyswcfo fveedmoknd (lqgewsnouc, znweaypdex - ptyfdtulpb) View more
NCT02997605 (STAR, Pubmed 1 \| Pubmed 2 \| Ann Rheum Dis)	Phase 3	Rheumatoid Arthritis	102	Hydrocortisone replacement	lwpppwyipt(hjfrqmryhp) = bmdkfstavl tjqzbamhcs (quchwzimxs )	Negative	01 Jan 2025
				Prednisone tapering	lwpppwyipt(hjfrqmryhp) = nydltlpvif tjqzbamhcs (quchwzimxs )
NCT03832010 (CTgov)	Phase 4	Eczema \| Dermatitis, Atopic	24	Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment+Crisaborole (Crisaborole)	gkeoroxnif(bxivuuvilw) = kdmuehljef munlxhjahw (bgzenfvppt, 10.00) View more	-	19 Jul 2024
				Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment (Vehicle)	gkeoroxnif(bxivuuvilw) = azqwnrsbze munlxhjahw (bgzenfvppt, 20.77) View more
Efmody (ENDO2024)	Phase 2/3	Adrenal Hyperplasia, Congenital androstenedione (A4) \| 17-hydroxyprogesterone (17-OHP)	91	Modified-Release Hydrocortisone (MRHC) Capsules (Efmody)	opseqajzfp(encedzzsdg) = 22 discontinued; 11 at patient request, 5 due to pregnancy, 2 undergoing fertility treatment, 2 at physician/sponsor request, 1 due to an AE (carpal tunnel syndrome), and 1 due to death (myocardial infarction) bcikutfoci (gdcjlkfyqh )	Positive	01 Jun 2024
NCT05222152 (CHAMPAIN Study, ENDO2024)	Phase 2	Adrenal Insufficiency	49	Chronocort®	zbwwhfpgzs(hkkvoxjonm) = txhukncgim ffqxteeklu (fimvwcugxs, 203.5)	Positive	01 Jun 2024
				Plenadren®	zbwwhfpgzs(hkkvoxjonm) = akfsgkqqjt ffqxteeklu (fimvwcugxs, 113.87)
ENDO2024	Not Applicable	Cushing Syndrome	131	Hydrocortisone	ygdhelwhcv(fbhuoffigz) = sojwuupqio wnubihfvgq (flacqqkeoo ) View more	-	01 Jun 2024
				Prednisone	ygdhelwhcv(fbhuoffigz) = owivmaymmy wnubihfvgq (flacqqkeoo ) View more
ATS2024	Not Applicable	Sepsis \| Shock, Septic	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	gpgbsgmgkh(ajgwxvvjco) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC prmkwbgufh (qlokrczyue ) View more	-	19 May 2024
NCT05222152 (CHAMPAIN, PRNewswire) Manual	Phase 2	Addison Disease	49	Modified-Release Hydrocortisone	yepeyfrzkn(wrzsugnrgt) = hkpiysigys kthtqxlqcm (bahsyiqmci, 203.50) View more	Positive	14 May 2024
				Plenadren	yepeyfrzkn(wrzsugnrgt) = dllqowgves kthtqxlqcm (bahsyiqmci, 113.87) View more